696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies

Authors

Vimal Prajapati

Published

August 1, 2024

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

British Journal of Dermatology

Topics

Immunology And Allergy

DOI

10.1093/bjd/ljae266.070

696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies

Authors

Vimal Prajapati

Published

August 1, 2024

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

British Journal of Dermatology

Topics

Immunology And Allergy

DOI

10.1093/bjd/ljae266.070

Paper

Paper

Paper

Paper

696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies

Supporters

Journal

Topics

DOI

696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies

Supporters

Journal

Topics

DOI